REGENERX BIOPHARMACEUTICALS
RGN
RGN was delisted on the 22nd of December, 2010.
2 hedge funds and large institutions have $25K invested in REGENERX BIOPHARMACEUTICALS in 2019 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 0 reducing their positions, and 1 closing their positions.
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
19% less capital invested
Capital invested by funds: $31K → $25K (-$6K)
33% less funds holding
Funds holding: 3 → 2 (-1)
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Colony Group
Boston,
Massachusetts
|
-$2K |
RGN Hedge Fund Activity: Q3 2019 in Review
2 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in REGENERX BIOPHARMACEUTICALS (RGN) for Q3 2019, worth a combined $25K — down 19% from $31K a quarter earlier.
Fund positioning in RGN was balanced in Q3 2019: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.
The largest seller was Colony Group, exiting entirely with an estimated $2K sold.
- 2 institutional investors held REGENERX BIOPHARMACEUTICALS (RGN) as of Q3 2019, down from 3 in Q2 2019.
- Funds reported $25K of REGENERX BIOPHARMACEUTICALS stock for Q3 2019, down 19% quarter-over-quarter.
- 1 fund opened new REGENERX BIOPHARMACEUTICALS positions in Q3 2019 and 1 closed out, a net change of 0 holders.
- The largest REGENERX BIOPHARMACEUTICALS seller in Q3 2019 was Colony Group, an estimated $2K sold.
Based on aggregated 13F filings for Q3 2019.